A SAFE AND EFFECTIVE METHOD FOR TREATMENT OF PSORIATIC ARTHRITIS WITH A SPECIFIC ANTI-IL23 ANTIBODY
MA50580B1Active Publication Date: 2026-09-30JANSSEN BIOTECH INC
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- MA50580
- Authority / Receiving Office
- MA · MA
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-11-06
- Filing Date
- 2018-11-06
- Publication Date
- 2026-09-30
- Estimated Expiration
- 2038-11-06
Abstract
The invention relates to a method of treating psoriatic arthritis in the patient by administering a specific IL-23 antibody, for example guselkumab, in an amount proven to be clinically safe and clinically effective, which enables the patient to achieve a significant improvement in the ACR20 / 50 / 70, PASI70 / 90 / 100, MDA, HAQ-DI, SF-36 PCS, MCS, LEI / dactylitis, PASDAS, GRACE, mCPDAI, DAPSA or RAPID3 criteria, as measured 16, 24, 32, 40 and 48 weeks after initial treatment.
Need to check novelty before this filing date? Find Prior Art